New York, January 11, 2026, 14:15 EST — Market closed.
- Novartis ADRs ended the session slightly higher, up 0.1% to $141.54.
- Novartis announced plans to open a radioligand therapy manufacturing plant in Winter Park, Florida, expected to be operational by 2029.
- Novartis CEO Vas Narasimhan will speak at the J.P. Morgan Healthcare Conference on Jan. 12. The company is scheduled to release its full-year results on Feb. 4.
Novartis AG’s U.S.-listed shares (NVS) closed Friday mostly flat. Still, the stock starts the new week with a notable development: the company announced a new U.S. manufacturing facility for its radioligand cancer therapies.
The timing matters because radioligand therapy demands tight logistics — every dose is tailored to a single patient, and the clock is ticking the moment it’s prepared. More capacity and smarter location choices mean fewer missed or delayed treatments. Novartis has been pushing that point hard, and investors are taking note.
The timing coincides with the J.P. Morgan Healthcare Conference in San Francisco, where drugmakers outline their outlook and bankers ramp up deal chatter. Novartis’ CEO is scheduled to speak on Monday.
Novartis is set to open a 35,000-square-foot radioligand therapy (RLT) manufacturing plant in Winter Park, Florida—its fourth such facility in the U.S. The company expects the site to be operational by 2029. This move is part of a larger $23 billion U.S. investment plan unveiled in April 2025.
“Building this new facility in Florida marks an important step,” Narasimhan said in the statement, highlighting delivery “with speed and reliability.” Novartis said the site is designed to maintain its track record of administering over 99% of doses on the scheduled day, even as demand rises. Novartis
The company characterized RLT as a precision method that combines a tumor-targeting molecule with a therapeutic radioisotope, directing radiation straight to the tumor while minimizing damage to healthy tissue. The urgency involved is why Novartis stressed locating near treatment centers and transport hubs.
Novartis claims to be the sole company with two FDA-approved RLT therapies and is testing treatments for several cancers, including prostate, breast, colon, lung, brain, and pancreatic. The company has been growing its RLT presence in Indiana and New Jersey, and wrapped up a new facility in California last November.
Florida’s Secretary of Commerce, J. Alex Kelly, highlighted the state’s focus on higher education and life sciences as key to landing the project, calling it “an incredible opportunity” for the local ecosystem. Novartis also pointed to Florida’s “regulatory and policy environment” as a boost for pharmaceutical innovation. Novartis
Traders are also keeping an eye on the conference scene. Healthcare dealmakers are targeting 2026 for major transactions, citing a softer antitrust stance and fresh enthusiasm from boards. “That has made people dust off the playbook,” JPMorgan healthcare banker Jeremy Meilman told Reuters. Reuters
The Florida project won’t boost earnings anytime soon. It’s not set to go live until 2029, with plenty of execution risks lingering — think delays, permitting hurdles, staffing challenges, and the tricky logistics of radioactive supply chains. Pricing and reimbursement for expensive cancer treatments add another layer of uncertainty.
Monday at 9 a.m. local time in San Francisco, the company will present, with investors eager for updates on RLT demand, pipeline progress, and capex plans. The real spotlight, though, is Feb. 4, when Novartis releases its Q4 and full-year 2025 results.
